Using AI to predict Parkinson's risk in patients with REM sleep behavior disorder
Official title: Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder
Run by Insel Gruppe AG, University Hospital Bern · NCT06629207 · Data updated 2026-11-12
This study is testing if using artificial intelligence to analyze brain scans can help identify people with REM sleep behavior disorder who are at risk of developing Parkinson's disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 1 site (Bern) |
| Status | Recruiting |
| Started | October 7, 2024 |
| Main results expected | August 1, 2026 |
| Study ends | August 1, 2026 |
| Registry record updated | November 8, 2024 |
| Trial ID | NCT06629207 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with idiopathic REM sleep behavior disorder who have not yet developed Parkinson's disease or other neurodegenerative disorders.
✕Probably not a fit
Patients with a known diagnosis of Parkinson's disease or other neurodegenerative disorders will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to document the progression of REM sleep behavior disorder (RBD) and identify clinical and imaging biomarkers that may indicate the risk of developing Parkinson's disease and related conditions. Participants will undergo clinical evaluations and two imaging procedures, including PET/CT and MRI, to gather data. The study utilizes artificial intelligence to analyze imaging results and develop predictive models for patient stratification based on their risk of conversion to a-synucleinopathy disorders.
Why it matters
Potential benefit: If successful, this study could provide a reliable method for early identification of patients at risk for Parkinson's disease and related disorders.
How similar studies have gone: Other studies have shown promise in using artificial intelligence for predictive modeling in neurodegenerative diseases, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders 2. Written informed consent Exclusion Criteria: 1. Known diagnosis of PD or other neurodegenerative disorder 2. Unequivocal signs of parkinsonism on examination 3. Narcolepsy or other known causes of RBD 4. Moderate to severe obstructive sleep apnea 5. Abnormal neurological or MRI examination
Where it's running
-
Inselspital, University Clinic for Nuclear Medicine
Bern, Switzerland Recruiting
Study contacts
- Principal investigator: Kuanggyu Shi, Prof. Dr. ing. — University Bern, Inselspital, Center for Artificial Intelligence in Medicine
- Study coordinator: Axel Rominger, Prof. Dr. med.
- Email: axel.rominger@insel.ch
- Phone: +41 316322610
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Exploring gut immunity's role in neurologic diseases
This study is trying to see how immune cells in the gut might affect diseases like Multiple Sclerosis and Parkinson's by looking at tissue samples from people having a colonoscopy.
-
Increasing physical activity in patients at risk of Parkinson's disease using a smartphone app
This study is testing a smartphone app to help people at risk of Parkinson's disease increase their physical activity and exercise intensity over two years.
-
National Parkinson's biobank with whole genome sequencing and patient-derived stem-cell testing
This project will test whether combining whole genome sequencing and patient-derived stem cells can help find rare genetic changes linked to Parkinson's disease and REM sleep behavior disorder.
-
Observing the progression of synucleinopathies
This study is tracking how synucleinopathies, a group of brain diseases, progress in adults with symptoms like dizziness when standing up to better understand their development over time.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.